Prime Medicine appoints Svetlana Makhni as CFO effective April 16, 2026

Prime Medicine, Inc.

Svetlana Makhni named CFO; base salary $495K, sign-on bonus $40K, target bonus 40%.
Granted option to purchase 800K shares (time-based vesting over 4 years) and 100K milestone-based option.
Allan Reine steps down as principal financial officer but remains CEO.
Makhni has 20+ years biotech/healthcare CFO and investment banking experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.